On the 14th of September, Point72 Asset Management added 702 thousand Bicycle Therapeutics plc (NASDAQ:BCYC) shares for $13 million at an average price of $19.08 per share. Shares of Bicycle Therapeutics plc are up 2.20% since the transaction.
Point72 Asset Management's holding in Bicycle Therapeutics plc increased to about 1.1 million shares with the purchase.
Point72 Asset Management first bought Bicycle Therapeutics plc stock in the fourth quarter of 2019. Point72 Asset Management also owns Merck (MRK), MacroGenics, Inc. (NASDAQ:MGNX), PTC Therapeutics, Inc. (NASDAQ:PTCT) and uniQure N.V. (NASDAQ:QURE). Bicycle Therapeutics plc is its number fourteen position by number of shares and market value among biotechnology & life sciences stocks.
Other investors who also added to their Bicycle Therapeutics plc shares include Millennium Management. In contrast, Victory Capital Management and Squarepoint Ops reduced BCYC shares.
Point72 Asset Management has also recently increased their share in MacroGenics, Inc. The total value of the shares bought is estimated at around $67 million.
Point72 Asset Management also established new holdings in ANGI Homeservices Inc. (NASDAQ:ANGI), Dave & Busters Entertainment Inc (PLAY) and Fulcrum Therapeutics, Inc. (NASDAQ:FULC). Point72 Asset Management also increased their share in American Eagle Outfitters Inc (NYSE:AEO), The Children's Place, Inc. (NASDAQ:PLCE), Otonomy, Inc. (NASDAQ:OTIC) and Revolve Group , Inc. (NYSE:RVLV). The total value of the shares bought is estimated at around $254 million.